Paper Title
DAPAGLIFLOZIN: FOR THE TREATMENT OF TYPE - 2 DIABETES
Article Identifiers
Authors
Vahadane Ruchika Sheshrao , Wagh Pratik Laxman , Bhawar Sanjay. B
Keywords
Dapagliflozin, Type 2 diabetes, cardiovascular disease, Adverse event.
Abstract
Dapagliflozin ( Forxiga®) is a globally recognized treatment for type 2 diabetes, known for its high potency, reversibility, and selectivity as a sodium-glucose cotransporter-2 inhibitor. Dapagliflozin, taken orally once daily, is approved in the EU for use as monotherapy (in patients intolerant of metformin) and as an add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone are insufficient for adequate glycemic control. Dapagliflozin, whether used alone or in combination with other Antihyperglycemic agents, demonstrated effective glycemic control and led to reductions in body weight and blood pressure in a wide range of patients, as evidenced by numerous meticulously conducted clinical studies and their extensions. Dapagliflozin decreased the occurrence of cardiovascular (CV) death or hospitalization for heart failure (HHF), showed no negative impact on major adverse CV events (MACE), and potentially slowed the progression of renal disease compared to a placebo in individuals with confirmed atherosclerotic CV disease (CVD) or multiple CVD risk factors. Dapagliflozin was generally well received, exhibiting a minimal risk of hypoglycemia. While diabetic ketoacidosis (DKA), though infrequent, genital infections were more prevalent with dapagliflozin compared to the placebo. Due to its antihyperglycemic, cardioprotective, and potentially reno protective attributes, along with a generally well-tolerated profile, dapagliflozin emerges as a significant choice for treating a Adiverse range of patients, irrespective of their cardiovascular history.
Downloads
How To Cite (APA)
Vahadane Ruchika Sheshrao , Wagh Pratik Laxman, & Bhawar Sanjay. B (January-2024). DAPAGLIFLOZIN: FOR THE TREATMENT OF TYPE - 2 DIABETES. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 9(1), d130-d139. https://ijnrd.org/papers/IJNRD2401317.pdf
Issue
Volume 9 Issue 1, January-2024
Pages : d130-d139
Other Publication Details
Paper Reg. ID: IJNRD_213202
Published Paper Id: IJNRD2401317
Downloads: 000121988
Research Area: Pharmacy
Country: Ahemadnagar, MAHARASHTRA, India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2401317.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2401317
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.
Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: October 2025
Current Issue: Volume 10 | Issue 10 | October 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 31-Oct-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
